Establishment of patient-derived models of metastatic appendiceal cancers (#208)

5:35 PM

King Ho Leong

Advancing Plasma Proteomics: Olink, Nanoparticle Enrichment, and Soluble HLA Profiling for Precision Biomarker Discovery (#209)

5:35 PM

Terry Lim

Beyond the androgen receptor; a reprogramming framework identifies novel master-regulator networks driving aggressive prostate cancer lineage (#210)

5:35 PM

Natalie L Lister

50-marker multiplexed imaging transforms the potential of circulating tumor cells to guide precision oncology (#211)

5:35 PM

John G Lock

Deep multiplex immunofluorescence of DNA damage response identifies targetable synthetically lethal interactions (#212)

5:35 PM

Timothy J. Mann

Deciphering ovarian cancer origins in the fallopian tube (#213)

5:35 PM

Laura Marruecos

Retrospective single cell lineage tracing with expressed somatic mitochondrial variants (#214)

5:35 PM

Cal McCrimmon

Breast cancer risk factors and Pik3ca mutations promote expansion of estrogen receptor positive luminal progenitors   (#215)

5:35 PM

Conor McGuinness

Defining the role of the immune system in early breast cancer (#216)

5:35 PM

Sarah McLucas

Translational reprogramming disrupts mitosis to drive SMAD4-deficient oesophageal adenocarcinoma (#217)

5:35 PM

Julia Milne

Evaluating PTEN mutations as a predictor of response to combinatorial therapy in ovarian cancer (#218)

5:35 PM

Leean Miranda

Development of novel cellular models to investigate the biological mechanism of breast cancer polygenic risk. (#219)

5:35 PM

Ashleigh Monson

Peroxisome Biology in IDH1 Mutated Cancer: Mechanisms and Targetable Vulnerabilities   (#220)

5:35 PM

MAHTA MORAGHEBI

Loss of tristetraprolin drives the progression to treatment resistant prostate cancer by altering stress response pathways (#221)

5:35 PM

Katherine L Morel

Tryptophan metabolism fuels one-carbon metabolism and regulates serine synthesis in triple-negative breast cancer: A novel druggable pathway (#222)

5:35 PM

Jamshid Motalebzadeh

  BCL6 as driver of glioma with insights from a GEM-CLeM model system (#223)

5:35 PM

Naychi Myo Min

RUNX1 and beyond: genetic mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia (#224)

5:35 PM

Zuhal ZN Naderi

AMPK drives metabolic adaptation and resistance to KRAS inhibition in pancreatic cancer (#225)

5:35 PM

David M Nash

DUSP4 copy loss: an alternate mediator of ERK/MAPK signaling activation and a novel driver of colorectal cancer (#226)

5:35 PM

Kristen A Needham

Investigating the heterogeneity of acute myeloid leukaemia response to different classes of therapy using lineage tracing. (#227)

5:35 PM

Daniel Neville

Optimising a Decellularized Bovine Scaffold Model for Culturing Bone Metastases and Drug Screening (#228)

5:35 PM

Holly Newman

Suppressing vasculogenic mimicry in claudin-low breast cancer by targeting Neuropilin-1 (#229)

5:35 PM

Ngoc Minh Long Nguyen

Haematopoietic stem cell derived CAR-T cells for improved anticancer immunity (#230)

5:35 PM

Phillip Nguyen

NRF2 co-opts the SWI/SNF complex to drive liver cell plasticity (#231)

5:35 PM

Athena Jessica S Ong

ChemProTarget: A Cancer-Agnostic Pipeline Linking Undruggable Cancer Vulnerabilities to On-Target Covalent Small Molecules (#232)

5:35 PM

John Paul Ong

Mitochondrial DNA Mutations Are Associated with Impaired Mitochondrial Fitness and TKI Sensitivity in CML (#233)

5:35 PM

Ilaria Stefania Pagani

Genomic complexity and adaptive alterations underpin drug resistance in myeloid blast crisis chronic myeloid leukaemia cell lines (#234)

5:35 PM

Ilaria Stefania Pagani

Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response (#235)

5:35 PM

Brooke Pereira

Mini-Tumours, Major Impact: Patient-derived breast tumour organoids for precision medicine (#236)

5:35 PM

Yohanka Perera

Harnessing phosphoproteomic profiling for target discovery in high-risk osteosarcoma: A pathway to novel therapies? (#237)

5:35 PM

Callum M Perkins

Rationalising the inclusion of HDAC inhibitors with standard-of-care chemotherapy for high-risk neuroblastoma (#238)

5:35 PM

Monica Phimmachanh

Determining the role of autophagy in p-PKCδ mediated chemoresistance in triple negative breast cancer (#239)

5:35 PM

Emily Phipps

Characterising genomic heterogeneity in KRAS-mutant lung adenocarcinoma (#240)

5:35 PM

Siddharth Pruthi

Clonal heterogeneity of drug tolerant persisters following targeted therapy in non-small cell lung cancer (#241)

5:35 PM

Sunniyat Rahman

Targeting a redox protein, thioredoxin reductase 3, sensitizes triple-negative breast cancers to EGFR inhibitors. (#242)

5:35 PM

Prahlad Raninga

Extracellular vesicle-associated miRNA biomarkers improve the early detection of ovarian cancer (#243)

5:35 PM

Gregory E Rice

Pancreatic cancer secretome reveals PCSK9 as a co-target to sensitise tumours to chemotherapy and reduce metastasis (#244)

5:35 PM

Shona Ritchie

Expanding the utility of PARP inhibitors using combination therapy with androgen receptor signalling inhibitors in prostate cancer (#245)

5:35 PM

Mahsa Rostamiandelavar

Dissecting the tumour-neural microenvironment in prostate cancer (#246)

5:35 PM

Lauren Ryan

Targeting the nucleoli as a strategy to treat ovarian cancer (#247)

5:35 PM

Elaine Sanij

Testing the efficacy of Neuropilin-1 inhibition in pre-clinical models of claudin-low breast cancer   (#248)

5:35 PM

Samar Sanjabi

Using human and bioengineered skin to elucidate mechanisms in melanocyte and melanoma subpopulations that drive cancer initiation and progression (#249)

5:35 PM

Adriana Sanna

Investigating the role of clusterin in platinum-treated ovarian cancer (#250)

5:35 PM

Jessica Scott

Prioritizing PI3K pathway inhibitors for PTEN-mutant breast cancer (#251)

5:35 PM

Kaveesha Senasinghe

FGFR2 spatial isoforms in tumour progression and prognosis, and emerging novel target in endometrial cancer precision therapy (#252)

5:35 PM

Asmerom T Sengal

Genomic guided therapies in oesophageal adenocarcinoma (#254)

5:35 PM

Sowmya L Sharma

Targeted CDK4/6 inhibition to improve outcomes in triple negative breast cancer (#255)

5:35 PM

Hasha Simad

Interrogating the immune microenvironment changes during breast cancer development using multiple genetically engineered mouse models (#257)

5:35 PM

Xiaoyu (Shirley) Song

Identifying drugs that boost immunogenicity of prostate cancer bone metastases via high-throughput screening (#258)

5:35 PM

Aliye Tabatabaee

Clinical candidate drug NXP800 inhibits HSF1 pathway and activates the Integrated Stress Response (ISR) via GCN2 in ARID1A mutant ovarian cancer (#259)

5:35 PM

Maria E Taskinen

Investigating transcript diversity as a driver of melanoma progression and metastasis using nanopore long-read RNA sequencing (#260)

5:35 PM

Jun Yao Teow

CHK1 inhibitor with low dose Hydroxyurea Amplifies Replication Stress and Drives a Novel Pan-nuclear Ataxia Telangiectasia Mutated Phenotype (#261)

5:35 PM

Max J Thompson

Precision mRNA-LNP therapeutics for cancer (#262)

5:35 PM

Hannah Tompkins

Identifying and targeting treatment response mechanisms to improve Gemcitabine/Abraxane performance in Patient-Derived Models of Pancreatic Cancer (#263)

5:35 PM

Alice Tran

Optimising CUT&RUN to Dissect the Role of FOXA1 in the Normal Breast: Binding Patterns in ER+ Luminal Progenitor Cells. (#264)

5:35 PM

Ella R Treherne

Targeting macrophage-specific vulnerabilities to reduce relapse following AML differentiation therapy. (#265)

5:35 PM

Jake H Tremewen

Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq (#266)

5:35 PM

Michael Trpceski

Investigating therapeutically targetable mechanisms of SNAI1-driven Acute Myeloid Leukaemia. (#267)

5:35 PM

Lynda LT Truong

Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor and chemotherapeutic efficacy in pancreatic cancer (#268)

5:35 PM

Victoria M Tyma

Cell cycle inhibition promotes Natural Killer cell-mediated cytotoxicity against colorectal liver metastasis organoids (#269)

5:35 PM

Robin Wagner

Temporal single clone analyses reveal a Xlr4b driven HSPC program that facilitates T-cell reconstitution following transplantation. (#270)

5:35 PM

Elanor N Wainwright

An intronic AR responsive region of ZBTB16 but not ZBTB16 itself is critical for AR mediated tumour suppression in ER positive breast cancer (#271)

5:35 PM

Maliha Wajahat

Y box binding protein 1 mediated modulation of chromosomal instability in cancer (#272)

5:35 PM

Selena Wang

Investigating therapy-induced isoform-switching in melanoma using CRISPR-Cas13. (#273)

5:35 PM

Naomi Warren

Angiotensin converting enzyme-2 suppresses cancer growth in mice with a secondary liver cancer (#274)

5:35 PM

Muditha N Wijesinghe

Thyroid hormone receptor beta as a Metabolic Driver in triple-negative breast cancer: Implications for the clinical use of TRβ agonists. (#275)

5:35 PM

Andrew J. Woo

Targeting tumour fibrosis with a small molecule ROCK2 inhibitor to improve radiotherapy response in head and neck cancer (#276)

5:35 PM

Dannel Yeo

Unleashing the analytical potential of ovarian ascites via deep multiplexed imaging (#277)

5:35 PM

Ye (Gloria) Zheng